Pemetrexed plus Platinum Chemotherapy with or Without Immuno Responses of Bevacizumab plus Cisplatin for the Non-Squamous Non-Small-Cell Lung Cancer Patients with Malignant Pleural Effusions Therapy in Non-Squamous NSCLC: Descriptive Safety Analysis

被引：0
|
作者：
Li, X.
Li, J.
机构：
[1] Chinese Acad Med Sci, Natl Canc Ctr, Canc Hosp, Med Oncol, Beijing, Peoples R China
[2] Peking Union Med Coll, Beijing, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
bevacizumab; Cisplatin; malignant pleural effusion;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.01-041
引用
收藏
页码：S2084 / S2084
页数：1
相关论文
共 50 条
  • [21] An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer
    Nuijten, Mark J. C.
    Aultman, Rick
    de Castro Carpeno, Javier
    Vergnenegre, Alain
    Chouaid, Christos
    Walzer, Stefan
    Siebert, Uwe
    CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (11) : 2193 - 2201
  • [22] INDIRECT COMPARISON OF EFFICACY, SAFETY, AND COST: PEMETREXED/CISPLATIN VERSUS BEVACIZUMAB/GEMCITABINE/CISPLATIN IN PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
    Orlando, Mauro
    Barraclough, Helen
    Orlov, Sergey
    Rajan, Narayan
    Davey, Peter
    Kanivets, Yana
    Han, Baoguang
    Brnabic, Alan
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1232 - S1233
  • [23] EFFICIENCY OF CISPLATIN, PEMETREXED, AND BEVACIZUMAB AS FIRST-LINE TREATMENT FOR JAPANESE ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER PATIENTS
    Shiraishi, Yoshimasa
    Hirai, Humihiko
    Yamaguchi, Masafumi
    Morodomi, Yosuke
    Toyozawa, Ryo
    Inamasu, Eiko
    Kojo, Miyako
    Toyokawa, Gouji
    Takenaka, Tomoyoshi
    Seto, Takashi
    Takenoyama, Mitsuhiro
    Ichinose, Yukito
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S488 - S488
  • [24] Bevacizumab plus Weekly Paclitaxel with or Without Carboplatin for Previously-treated Non-squamous Non-Small Cell Lung Cancer
    Hata, Akito
    Katakami, Nobuyuki
    Tanaka, Kosuke
    Takeshita, Jumpei
    Matsumoto, Takeshi
    Monden, Kazuya
    Nagata, Kazuma
    Masago, Katsuhiro
    Kaji, Reiko
    Fujita, Shiro
    Tachikawa, Ryo
    Otsuka, Kyoko
    Otsuka, Kojiro
    Tomii, Keisuke
    ANTICANCER RESEARCH, 2014, 34 (1A) : 275 - 281
  • [25] First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naive patients
    Leon, Luis
    Vazquez, Sergio
    Manuel Gracia, Jose
    Casal, Joaquin
    Lazaro, Martin
    Luis Firvida, Jose
    Amenedo, Margarita
    Santome, Lucia
    Macia, Sonia
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (10) : 1389 - 1396
  • [26] Bevacizumab/PD-1 inhibitor plus chemotherapy as first-line treatment of advanced non-squamous non-small-cell lung cancer
    Wang, Jing
    Chen, Qin
    Wang, Xinyue
    Huang, Dingzhi
    Jiang, Richeng
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2023, 12 (05)
  • [27] Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab-paclitaxel for non-squamous non-small cell lung cancer with malignant pleural effusion
    Tamiya, Motohiro
    Tamiya, Akihiro
    Suzuki, Hidekazu
    Taniguchi, Yoshihiko
    Katayama, Kanako
    Minomo, Shojiro
    Nakao, Keiko
    Takeuchi, Naoko
    Matsuda, Yoshinobu
    Naito, Yujiro
    Shiroyama, Takayuki
    Okamoto, Norio
    Okishio, Kyoichi
    Kumagai, Toru
    Atagi, Shinji
    Imamura, Fumio
    Hirashima, Tomonori
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (04) : 1106 - 1112
  • [28] Comparative effectiveness of bevacizumab plus cisplatin-based chemotherapy versus pemetrexed plus cisplatin treatment in East Asian non-squamous non-small cell lung cancer patients applying real-life outcomes
    Chang, Gee-Chen
    Ahn, Myung-Ju
    Wright, Elaine
    Kim, Heung Tae
    Kim, Joo-Hang
    Kang, Jin Hyoung
    Kim, Sang-We
    Sherman, Steven
    Walzer, Stefan
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2011, 7 : 34 - 40
  • [29] Tolerance and efficacy of branded generic pemetrexed maintenance in Indian patients of metastatic non-squamous non-small-cell lung cancer
    Sehrawat, Amit
    Parthasarathy, K. M.
    Gupta, Deni
    Gera, Arun
    INDIAN JOURNAL OF CANCER, 2019, 56 (03) : 276 - 278
  • [30] Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced/metastatic non-squamous non-small-cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group
    Kentepozidis, N.
    Kotsakis, A.
    Soultati, A.
    Agelaki, S.
    Christophylakis, Ch.
    Agelidou, M.
    Chelis, L.
    Papakotoulas, P.
    Vamvakas, L.
    Zafiriou, Z.
    Samonis, G.
    Georgoulias, V.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (03) : 605 - 612
12345